Escitalopram in breast cancer patients

Effect of escitalopram on pain, anxiety and depression in patients with breast cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150630022991N14

Enrollment

Registered

2018-11-22

Start date

2018-11-06

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant neoplasm of breast. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group: 10 milligram per day escitalopram capsule manufactured in Abidi Pharmaceutical Company for four weeks. Intervention 2: Control group: One placebo capsule containing

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Newly diagnosed breast cancer patients With depression and anxiety symptoms

Exclusion criteria

Exclusion criteria: Previous history of high mood Suicidal thoughts Mental retardation Dementia Substance dependence

Design outcomes

Primary

Measure	Time frame
Pain severity. Timepoint: At the beginning of the study and four weeks after intervention. Method of measurement: Visual Analogue Scale.;Depressive symptoms. Timepoint: At the beginning of the study and four weeks after intervention. Method of measurement: Hospital Anxiety and Depression Scale.;Anxiety symptoms. Timepoint: At the beginning of the study and four weeks after intervention. Method of measurement: Hospital Anxiety and Depression Scale.	—

Measure

Time frame

Pain severity. Timepoint: At the beginning of the study and four weeks after intervention. Method of measurement: Visual Analogue Scale.;Depressive symptoms. Timepoint: At the beginning of the study and four weeks after intervention. Method of measurement: Hospital Anxiety and Depression Scale.;Anxiety symptoms. Timepoint: At the beginning of the study and four weeks after intervention. Method of measurement: Hospital Anxiety and Depression Scale.

—

Secondary

Measure	Time frame
Escitalopram- related side effects. Timepoint: In four weeks of intervention period. Method of measurement: Medical visit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSussan Moudi, MD

Babol University of Medical Sciences

sussan.mouodi@gmail.com+98 11323268823

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026